Volume No. :   10

Issue No. :  4

Year :  2018

ISSN Print :  0975-234X

ISSN Online :  0975-4377


Registration

Allready Registrered
Click to Login

Recent trends in role of superdisintegrants to formulation of solid oral dosage form



Address:   Debjit Bhowmik1*, Rishab Bhanot1, K.P. Sampath Kumar2
1Himachal Institute of Pharmaceutical Education and Research, Nadaun, Hamirpur, H.P.
2Department of Pharmacy, Coimbatore Government Medical College, Coimbatore
*Corresponding Author
DOI No: 10.5958/0975-4377.2018.00036.8

ABSTRACT:
Disintegrating agents are substances routinely included in the tablet formulations to aid in the break up of the compacted mass when it is put into a fluid environment. They promote moisture penetration and dispersion of the tablet matrix. In recent years, several newer agents have been developed known as “Superdisintegrants”. These newer substances are more effective at lower concentrations with greater disintegrating efficiency and mechanical strength. On contact with water the superdisintegrants swell, hydrate, change volume or form and produce a disruptive change in the tablet. Effective superdisintegrants provide improved compressibility, compatibility and have no negative impact on the mechanical strength of formulations containing high-dose drugs. The orally disintegrating tablet is a solid dosage form that disintegrates and dissolves in the mouth without the need of water within 60 seconds or less. According to the US Food and Drug Administration, orally disintegrating tablet is "a solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue" By FDA guidance, orally disintegrating tablet should have an in vitro disintegration time of 30 seconds or less, based on the US Pharmacopeia disintegration test method.
KEYWORDS:
Superdisintegrants, Solid oral dosage form
Cite:
Debjit Bhowmik, Rishab Bhanot, K.P. Sampath Kumar. Recent trends in role of superdisintegrants to formulation of solid oral dosage form. Res. J. Pharm. Dosage Form. & Tech. 2018; 10(4): 245-252.
[View HTML]     



Visitor's No. :   162401